Sustained-release buprenorphine solutions
US10022367B2 · kind B2 · utility
6Cited by
86References
49Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 9, 2015 |
| Grant date | Jul 17, 2018 |
| Priority date | — |
| Expiry date | Mar 9, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/36
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.